Among 13,294 treated adults with type 2 diabetes and established cardiovascular disease, 12.1% of those assigned Mounjaro experienced cardiovascular death, a nonfatal heart attack or a nonfatal stroke, compared with 13.0% assigned an older cardioprotective diabetes drug. On Friday, August 28, the Food and Drug Administration used those results to expand Mounjaro’s approval to include reducing major cardiovascular events in adults with type 2 diabetes who are at high risk.

The revised FDA label moves tirzepatide, Mounjaro’s active ingredient, beyond its original role as a glucose-lowering treatment. It now carries an explicit cardiovascular risk-reduction indication alongside medicines from the same broader incretin family that have already demonstrated heart benefits. The change matters because diabetes care increasingly treats blood sugar, weight, kidney function and cardiovascular risk as interconnected rather than separate problems.

But the result requires careful interpretation. Mounjaro produced an estimated 8% lower relative rate of the three-part cardiovascular endpoint than Trulicity, or dulaglutide, yet the confidence interval included no difference and the trial did not establish statistical superiority. The strongest conclusion is therefore that tirzepatide preserved cardiovascular protection while producing greater metabolic effects, not that it definitively prevents more heart attacks or strokes than every alternative.

What the FDA changed

Mounjaro was first approved in 2022 to improve blood-sugar control in adults with type 2 diabetes and later expanded to patients 10 and older. The new indication applies to adults with type 2 diabetes at high cardiovascular risk and covers cardiovascular death, nonfatal myocardial infarction and nonfatal stroke. Lilly markets the same molecule under the Zepbound name for obesity, but Friday’s action applies specifically to Mounjaro and its diabetes label.

Tirzepatide activates receptors for two gut-derived hormones: glucose-dependent insulinotropic polypeptide, or GIP, and glucagon-like peptide-1, or GLP-1. The label says that this dual action enhances glucose-dependent insulin secretion, reduces glucagon, lowers food intake and body weight, and delays gastric emptying. Those effects can improve several cardiovascular risk factors, but biological plausibility alone is not proof that a medicine prevents clinical events; that evidence had to come from a long outcomes trial.

The approval places Mounjaro more directly into a treatment framework that already favors medicines with demonstrated cardiovascular benefit for many patients with diabetes and atherosclerotic disease. Current care standards recommend a GLP-1 receptor agonist with proven benefit, an SGLT2 inhibitor, or both when cardiovascular or kidney risk is prominent. A labeled indication can make that evidence easier for clinicians, insurers and health systems to incorporate into prescribing rules, although it does not guarantee access.

A demanding active-comparator trial

The pivotal SURPASS-CVOT study was designed as a double-blind, event-driven comparison rather than a placebo-controlled trial. Investigators randomized 13,299 adults in 30 countries to weekly tirzepatide, titrated to as much as 15 milligrams, or weekly dulaglutide at 1.5 milligrams. Participants had lived with diabetes for an average of about 15 years, and all had established atherosclerotic cardiovascular disease; nearly half had experienced a previous heart attack and 19% a previous stroke.

That comparator raised the evidentiary bar. Dulaglutide was not an inert control but a GLP-1 drug already approved to reduce major cardiovascular events. Over a median 210 weeks, the primary endpoint occurred in 803 Mounjaro recipients and 863 dulaglutide recipients in the label’s treated population. The hazard ratio was 0.92, with a 95.3% confidence interval from 0.83 to 1.01, meeting the prespecified test for noninferiority while missing the threshold for superiority.

The peer-reviewed trial report used a slightly smaller modified intention-to-treat population after excluding 134 randomized participants who did not meet eligibility criteria. It similarly recorded events in 12.2% of tirzepatide patients and 13.1% of dulaglutide patients, with P=0.003 for noninferiority and P=0.09 for superiority. An independent ACC review highlighted limited population diversity, the absence of a placebo arm and imbalances between groups as constraints on interpretation.

What the results prove

Noninferiority means the study ruled out a prespecified degree of unacceptable loss relative to dulaglutide; it does not mean the two drugs are identical. The trial’s upper confidence limit of 1.01 fell below the 1.05 noninferiority margin, supporting the conclusion that tirzepatide retained cardiovascular benefit. Because that interval also crossed 1.00, however, the observed 8% relative advantage could reflect chance rather than a true difference between treatments.

The absolute difference in the primary endpoint was about 0.9 percentage points over roughly four years. That is clinically relevant at population scale, but it is smaller and more uncertain than an “8% reduction” can sound when reported without its comparator and confidence interval. Component estimates also remained imprecise: cardiovascular death was 5.5% with Mounjaro and 6.2% with dulaglutide, while nonfatal heart attack and stroke rates were closer.

All-cause mortality was 8.5% with Mounjaro and 10.1% with dulaglutide, a hazard ratio of 0.84, but the label notes that this analysis was not controlled for the study’s family-wise statistical error rate. It is therefore supportive rather than definitive evidence. The trial was funded by Lilly, which also manufactures both drugs; the large randomized design and independent publication strengthen the evidence, while the sponsor’s commercial interest remains material context.

How the indication may change care

The practical attraction is consolidation. A clinician treating a patient with long-standing type 2 diabetes, obesity and cardiovascular disease can now choose a single weekly medicine with labeled evidence across glucose control, weight reduction and major cardiovascular risk. Tirzepatide is not a replacement for statins, blood-pressure therapy, antiplatelet treatment when indicated, smoking cessation or other standard measures; in the trial, 86% of participants already used statins and 83% used antiplatelet therapy.

That layered approach addresses a large disease burden. The CDC reports that cardiovascular disease accounted for 919,032 U.S. deaths in 2023, about one in every three deaths. Diabetes increases cardiovascular risk through overlapping pathways that include vascular inflammation, abnormal lipids, high blood pressure and kidney disease. The new label gives prescribers another evidence-backed option, but the size of an individual patient’s benefit will depend on baseline risk, tolerability and adherence.

Competition also matters. Novo Nordisk’s Wegovy gained a cardiovascular indication in 2024 for adults with cardiovascular disease and overweight or obesity, including people without diabetes, after a placebo-controlled trial; the FDA decision covered a different population. Oral semaglutide later received a diabetes cardiovascular-risk indication. Mounjaro now joins that expanding field with a head-to-head active-comparator result rather than a placebo comparison.

Cost, safety and unanswered questions

Coverage may determine how broadly the new indication changes practice. Lilly lists Mounjaro at $1,112.16 per fill before insurance, although net prices and patient costs vary substantially. Mounjaro sales reached $9.94 billion in Lilly’s second quarter, up 91% from a year earlier, according to Reuters. A cardiovascular indication could strengthen coverage arguments, but formularies may still require prior authorization or favor less expensive medicines.

Safety remains part of that choice. The updated label carries a boxed warning about thyroid C-cell tumors seen in rats and contraindicates use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Common trial problems included decreased appetite, constipation, vomiting and abdominal pain; the label also warns about pancreatitis, severe gastrointestinal reactions, dehydration-related kidney injury, gallbladder disease and worsening retinopathy during rapid glucose improvement.

Friday’s approval establishes that tirzepatide can reduce cardiovascular risk relative to a valid cardioprotective standard without sacrificing the metabolic advantages that made it widely used. It does not establish superiority over dulaglutide, reveal how well results will generalize to lower-risk or more diverse patients, or resolve affordability. The next meaningful evidence will come from real-world persistence, comparative access and trials testing whether newer incretin therapies can produce clearer advantages in heart and kidney outcomes.